Trending...
- Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales - 133
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- Emanuel Rose Launches Second Edition of The Agentic Pivot to Help Business Leaders Scale AI Adoption
USPTO allows 26 claims for ophthalmic formulations containing quaternary chitosan derivatives, marking a key step toward U.S. patent protection.
DALLAS - nvtip -- ClearSight Therapeutics Receives U.S. Patent Notice of Allowance for Ophthalmic Formulation Technology for unmet ocular diseases
Allowance marks an intellectual property milestone for innovative biopolymeric formulations developed for ocular applications
DALLAS, TX — [Release Date] — ClearSight Therapeutics today announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 19/380,414, titled "Ophthalmic Solution Containing Quaternary Chitosan Derivatives for Treating Ocular Diseases."
The notice, mailed September 29, 2026, allows 26 claims, including composition and method claims. The allowance represents an important step toward securing U.S. patent protection for ClearSight's ophthalmic formulation technology.
More on nvtip.com
"This allowance marks an important milestone for ClearSight and the science behind our ophthalmic formulations," said Patrick Smale, co-founder and CEO of ClearSight Therapeutics. "Building a strong intellectual property foundation supports our mission to develop innovative, accessible eye care solutions. We're encouraged by this progress as we continue advancing our technology."
"The formulation work focused on preserving the efficacy and key properties of quaternary chitosan in an ophthalmic solution," said co-inventor Nuria Jimenez, PhD, and co-founder & co-inventor Suchismita Acharya, PhD. "We're pleased that the examiner recognized the stability and antiviral activity data presented in the application, and we look forward to building on this scientific foundation to develop our eyedrop product to help people and expand our patent portfolio."
In its statement of reasons for allowance, the examiner cited evidence of acceptable formulation stability, preserved antiviral activity, and unexpectedly higher antiviral activity at 8- and 24-hour time points. These findings relate to evidence presented during patent examination and do not establish clinical efficacy or regulatory approval.
More on nvtip.com
About ClearSight Therapeutics
ClearSight Therapeutics is a Dallas/Fort Worth-based company founded in 2023 by eye care industry veterans and partners to develop better solutions for common eye conditions. The company is advancing next-generation over-the-counter ophthalmic products designed to address dryness, irritation, and ocular discomfort. For more information, visit clearsighttx.com.
Media Contact
ClearSight Therapeutics
info@clearsighttx.com
972-983-7761
Allowance marks an intellectual property milestone for innovative biopolymeric formulations developed for ocular applications
DALLAS, TX — [Release Date] — ClearSight Therapeutics today announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 19/380,414, titled "Ophthalmic Solution Containing Quaternary Chitosan Derivatives for Treating Ocular Diseases."
The notice, mailed September 29, 2026, allows 26 claims, including composition and method claims. The allowance represents an important step toward securing U.S. patent protection for ClearSight's ophthalmic formulation technology.
More on nvtip.com
- Law Offices of Larry E. Bray, P.A. Wins Fourth District Appeal Clarifying Limits of Florida's Offer of Judgment Statute
- Las Vegas Founder Ankit Tomar on Winning Bulk Buyers With Fast Custom Mockups
- Calculated Industries' ElectriCalc Pro Incorporates Latest 2026 National Electric Code
- Holiday Magic Returns to Downtown Downers Grove November 27-29
- What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
"This allowance marks an important milestone for ClearSight and the science behind our ophthalmic formulations," said Patrick Smale, co-founder and CEO of ClearSight Therapeutics. "Building a strong intellectual property foundation supports our mission to develop innovative, accessible eye care solutions. We're encouraged by this progress as we continue advancing our technology."
"The formulation work focused on preserving the efficacy and key properties of quaternary chitosan in an ophthalmic solution," said co-inventor Nuria Jimenez, PhD, and co-founder & co-inventor Suchismita Acharya, PhD. "We're pleased that the examiner recognized the stability and antiviral activity data presented in the application, and we look forward to building on this scientific foundation to develop our eyedrop product to help people and expand our patent portfolio."
In its statement of reasons for allowance, the examiner cited evidence of acceptable formulation stability, preserved antiviral activity, and unexpectedly higher antiviral activity at 8- and 24-hour time points. These findings relate to evidence presented during patent examination and do not establish clinical efficacy or regulatory approval.
More on nvtip.com
- Rural Health Transformation grant to support Nevada's maternal health
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
- LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
- Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
- Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
About ClearSight Therapeutics
ClearSight Therapeutics is a Dallas/Fort Worth-based company founded in 2023 by eye care industry veterans and partners to develop better solutions for common eye conditions. The company is advancing next-generation over-the-counter ophthalmic products designed to address dryness, irritation, and ocular discomfort. For more information, visit clearsighttx.com.
Media Contact
ClearSight Therapeutics
info@clearsighttx.com
972-983-7761
Source: ClearSight Therapeutics, Inc.
Filed Under: Health
0 Comments
Latest on nvtip.com
- LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
- Security Planning Tips For Your Holiday Event From Access Patrol Services
- Jade Promenade to Hold Groundbreaking Ceremony in Las Vegas Chinatown on December 8th
- Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
- Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
- Kitchen Table Economics: An Invitation to Think Differently
- Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
- CB Stuffer Announces Private Sale to Secure Future of Brand Growth
- NVision Optix Brings a Curated Approach to Luxury Eyewear and Eye Care in Reno-Tahoe
- Former Dentsu Exec Launches Consultancy to Bridge Brand Storytelling & Performance Execution
- Emanuel Rose Launches Second Edition of The Agentic Pivot to Help Business Leaders Scale AI Adoption
- The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
- Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
- Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition
- TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
- Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
- Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
- Step Into the Magic: Nevada Dance Company Brings The Nutcracker to Life This Thanksgiving Weekend
- ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
- Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
